Movement Alert｜Insmed Intraday Rise 12.6% in Regular Trading, Q3 Revenue Beat and Loss Narrowing Support Shares

Market Focus10-29

On October 29, Insmed rose 12.6% in Regular Trading, trading at $105.775/share, with turnover of $109 million.

The move followed the company’s latest quarterly results, with revenue rising well above the prior year and topping market expectations, even as per-share loss came in slightly worse than consensus.

For the quarter ended September 30, Insmed reported revenue of $524.4 million, up from $142.3 million a year earlier and above expectations near $500 million. Net loss narrowed to $0.46 per share from $1.75 a year earlier, while Brinsupri remained the main growth engine after contributing about $309 million in the prior quarter. The company had previously guided for full-year Brinsupri revenue of $1.25 billion to $1.40 billion and Arikayce revenue of $450 million to $470 million. Recent Japan commercialization progress for Brinsupri also adds support to the broader growth narrative.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment